Changing names
Mallinckrodt Baker will now be known as Avantor Performance Materials, company officials announced as they unveiled a new name and identity following the recent acquisition by an affiliate of New Mountain Capital.
Mallinckrodt Baker will now be known as Avantor Performance Materials, company officials announced today as they unveiled a new name and identity following the recent acquisition by an affiliate of New Mountain Capital, a New York-based private equity investment firm. The company manufactures and markets high-performance chemistries and materials around the world as J.T.Baker and Mallinckrodt Chemicals. These products are used in biotechnology and pharmaceutical production, microelectronics and photovoltaic manufacturing and in research, academic and quality control laboratories.
“Our new name conveys several very important ideals,” said Raj Gupta, executive chairman at Avantor and senior advisor at New Mountain Capital. “We chose Avantor because of its relevance to leadership. The word ‘Avant’ — as in avant-garde — evokes the bold ideas, energy, innovation and passion that we have as a company. The word ‘Tor’ means mountain and represents our aspiration to achieve new heights of performance and quality as well as our affiliation with New Mountain Capital.”
Ron Harding, president of Avantor, added, “It’s a new day for us and our new name sets the tone for our mission to enable customers to soar to new heights, take on new challenges and achieve new breakthroughs.”
For more details visit www.avantormaterials.com
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
